Changing systems for measuring activated clotting times: Impact on the clinical practice of heparin anticoagulation during cardiac surgery

Clinica Chimica Acta

Volumn 356, Issue 1-2, 2005, Pages 218-224

  Patteril, Mathew ^a   Stafford Smith, Mark ^a   Toffaletti, John G ^a   Bute, Barbara Phillips ^a   Milano, Carmelo A ^a   Welsby, Ian J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood coagulation tests; Cardiopulmonary bypass; Equipment design; Heparin; Human; Whole blood coagulation time

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG SAFETY; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONITORING; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL;

ADULT; AGED; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; COHORT STUDIES; CORONARY ARTERY BYPASS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 20344403488     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2005.01.019     Document Type: Article

References (19)

1. P.C. Hattersley Activated coagulation time of whole blood JAMA 196 1966 436 444
2. G.J. Despotis, A.L. Summerfield, J.H. Joist, L.T. Goodnough, S.A. Santoro, and E. Spitznagel Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations J Thorac Cardiovasc Surg 108 1994 1076 1082
3. T. Ammar, L.E. Scudder, and B.S. Coller In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time Circulation 95 1997 614 617
4. K.D. Pi Lack of correction between activated clotting time and plasma heparin during cardiopulmonary bypass Ann Surg 198 1983 115
5. G.J. Despotis, J.H. Joist, C.W. Hogue Jr., A. Alsoufiev, K. Kater, and L.T. Goodnough The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation J Thorac Cardiovasc Surg 110 1995 46 54
6. J.A. Young, C.T. Kisker, and D.B. Doty Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer Ann Thorac Surg 26 1978 231 240
7. J. Niinikoski, M. Laato, V. Laaksonen, J. Jalonen, and M.V. Inberg Use of activated clotting time to monitor anticoagulation during cardiac surgery Scand J Thorac Cardiovasc Surg 18 1984 57 61
8. B.F. Akl, G.M. Vargas, J. Neal, J. Robillard, and P. Kelly Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass J Thorac Cardiovasc Surg 79 1980 97 102
9. J.J. Verska Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis Ann Thorac Surg 24 1977 170 173
10. B.S. Bull, R.A. Korpman, W.M. Huse, and B.D. Briggs Heparin therapy during extracorporeal circulation: II J Thorac Cardiovasc Surg 69 1975 674 684
11. I.J. Welsby, E. McDonnell, H. El-Moalem, M. Stafford-Smith, and J.G. Toffaletti Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass J Clin Monit Comput 17 2002 287 292
12. A. Avendano, and J.J. Ferguson Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty J Am Coll Cardiol 23 1994 907 910
13. G.J. Despotis, J.H. Joist, C.W. Hogue, A. Alsoufiev, K. Kater, and L.T. Goodnough The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operations J Thorac Cardiovasc Surg 110 1995 46 54
14. J.G. Toffaletti, E.H. McDonnell, I.J. Welsby, I.R. Shearer, M.H. Sketch, and J.E. Tcheng Implementing a new method for activated clotting time: comparisons between the Hemachron and Actalyke-MaxACT systems Point Care 2 2003 125 128
15. G. Leyvi, L. Shore-Lesserson, D. Harrington, F. Vela-Cantos, and S. Hossain An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation Anesth Analg 92 2001 578 583
16. K. Shirota, T. Watanabe, Y. Takagi, Y. Ohara, A. Usui, and K. Yasuura Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass Artif Organs 24 2000 49 56
17. A. Koster, T. Fischer, M. Praus, H. Haberzettl, W.M. Kuebler, and R. Hetzer Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management Anesthesiology 97 2002 837 841
18. G.J. Despotis, J.H. Joist, C.W. Hogue Jr., A. Alsoufiev, D. Joiner-Maier, and S.A. Santoro More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT Thromb Haemost 76 1996 902 908
19. D.R. Jobes, G.L. Aitken, and G.W. Shaffer Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations J Thorac Cardiovasc Surg 110 1995 36 45